Major market opportunity

Kephera is developing technologies and products targeting global markets with significant value potential, including:

  • Point-of-care testing—$37 billion
  • Third-party assay development—$15 billion
  • Lyme disease—$2 billion
  • Neuroinfectious diseases—$1 billion

IP protection

Kephera has applied for patent protection for our MiCRIA™ Open POC platform, including our microfluidic assay device and rapid binding assay method. We also have a patent-pending Lyme disease test using a novel combination of antigens in an ELISA-based method.

Get involved

To learn more and to explore an investment relationship with Kephera Diagnostics, contact info@kephera.com

Terms and Conditions - Privacy Policy